- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04047836
Vaping High vs. Low Nicotine E-Liquid
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a within-subjects, crossover design of advanced electronic cigarette users in which we will examine nicotine pharmacokinetics, subjective effects, daily nicotine intake and nicotine titration, short-term cardiovascular effects, and toxicant exposure when participants are using low vs. high nicotine e-liquids.
Hypothesis 1: E-cigarette users will titrate their intake of nicotine such that they will inhale fewer aerosol toxicants and suffer less harm to health when using higher vs. lower nicotine content e-liquids.
Hypothesis 2: Compared to low nicotine, high nicotine e-liquid use will have similar cardiovascular effects throughout the day (due to compensatory behavioral changes), with similar effects on heart rate, blood pressure, and catecholamine release.
Hypothesis 3: Exposure to volatile organic compounds (VOCs) will be lower when vaping high nicotine e-liquids compared to low nicotine e-liquids.
Study Type
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
San Francisco, California, United States, 94110
- University of California, San Francisco
-
San Francisco, California, United States, 94110
- Zuckerberg San Francisco General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Healthy on the basis of medical history and limited physical examination, as described below:
- Heart rate < 105 beats per minute (BPM)*
- Systolic Blood Pressure < 160 and > 90*
Diastolic Blood Pressure < 100 and > 50*
*Considered out of range if both machine and manual readings are above/below these thresholds.
- Age: >= 21 years
- Age: <= 70 years
- Current regular user of open tank electronic cigarette (EC) (at least 20 times in the past 30 days) with e-liquid nicotine of 3-6 mg/mL.
- Non-smoker or non-daily cigarette smokers agreeing to abstain from cigarettes for the duration of the study.
- Saliva cotinine >50 ng/mL and/or NicAlert=6
- Carbon monoxide >= 5 ppm or per discretion of Principal Investigator
Exclusion Criteria:
- Medical
- Heart disease
- Seizures
- Cancer
- Thyroid disease (okay if controlled with medication)
- Diabetes
- Hepatitis B or C or Liver disease
- Glaucoma
- Kidney disease or urinary retention
- History of stroke
- An ulcer in the past year
- Active use of an inhaler for Asthma or Chronic obstructive pulmonary disease (COPD)
- Psychiatric conditions
- Current or past schizophrenia, and/or current or past bipolar disorder
- Major depression, current or within the past year
- Major personality disorder
- Participants with current or past minor or moderate depression and/or anxiety disorders will be reviewed by the PI and considered for inclusion
- History of psychiatric hospitalizations is not exclusionary, but study participation will be determined as per PI's approval
- Drug/Alcohol Dependence
- Alcohol or illicit drug dependence within the past 12 months with the exception of those who have recently completed an alcohol/drug treatment program
- Positive toxicology test for illicit drugs at the screening visit (THC & prescribed medications okay)
- Opioid replacement therapy (including methadone, buprenorphine, or other)
- Psychiatric medications
- Current regular use of any psychiatric medications with the exception of Selective Serotonin Reuptake Inhibitors (SSRIs) and serotonin-norepinephrine reuptake Inhibitors (SNRIs) and current evaluation by the PI that the participant is otherwise healthy, stable, and able to participate.
- Medications
- Use of medications that are inducers of nicotine metabolizing enzyme CYP2A6 (Example: rifampicin, carbamazepine, phenobarbital, and other anticonvulsant drugs).
- Use of sympatholytic medications for cardiovascular conditions including hypertension (Example: beta and alpha-blockers)
- Concurrent use of nicotine-containing medications
- Any stimulant medications (example: Adderall) generally given for attention deficit hyperactivity disorder (ADHD) treatment
- Other/Misc. Chronic Health Conditions
- Oral thrush
- Fainting (within the last 30 days)
- Other "life threatening illnesses" as per PI's discretion
- Pregnancy
- Pregnancy (self-reported and urine pregnancy test)
- Breastfeeding (determined by self-report)
- Concurrent participation in another clinical trial
- Inability to read and write in English
- Planning to quit vaping within the next 60 days
- Concurrent regular use of marijuana (occasional users of these products may be enrolled if they agree to abstain from their use during the period of the study)
- Use of other tobacco products, smokeless tobacco, pipes, cigars/cigarillos, blunts/spliffs (no more than 10 times in the past month and must agree to abstain from their use during the period of the study)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Low Nicotine
Using an electronic cigarette, the patient will participate in a standardized vaping session using 3 mg/ml nicotine e-liquid.
|
Participants will vape e-liquid with nicotine concentration of 3 mg/ml.
|
Other: Medium or High Nicotine
The patient will participate in a standardized vaping session using either an electronic cigarette with 18 mg/ml nicotine e-liquid or a JUUL device with a JUUL e-liquid pod.
|
Participants will vape either e-liquid with nicotine concentration of 18 mg/ml or a JUUL device with JUUL pod of 59 mg/ml nicotine e-liquid.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cardiovascular Effects: Heart Rate
Time Frame: Days 1-3 of each Arm
|
Participant heart rate will be measured in beats per minute throughout the inpatient stay.
|
Days 1-3 of each Arm
|
Nicotine Exposure
Time Frame: Day 1 of each Arm
|
Plasma nicotine area under curve (AUC) (ng/ml*h)
|
Day 1 of each Arm
|
Cardiovascular Effects: Systolic Blood Pressure
Time Frame: Day 2 of each Arm
|
Participant systolic blood pressure will be taken for 24 hours during ad-lib e-cigarette use.
|
Day 2 of each Arm
|
Cardiovascular Effects: Diastolic Blood Pressure
Time Frame: Day 2 of each Arm
|
Participant diastolic blood pressure will be taken for 24 hours during ad-lib e-cigarette use.
|
Day 2 of each Arm
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Vaping Topography: Puff Number
Time Frame: Days 1-3 of each Arm
|
Vaping topography measures will be obtained from self-reported participant vaping log during the ad libitum sessions and measured as puffs per minute.
|
Days 1-3 of each Arm
|
Vaping Topography: Puff Duration
Time Frame: Days 1-3 of each Arm
|
Vaping topography measures will be obtained from self-reported participant vaping log during the ad libitum sessions and measured as seconds per puff.
|
Days 1-3 of each Arm
|
Vaping Topography: Inter-Puff Interval
Time Frame: Days 1-3 of each Arm
|
Vaping topography measures will be obtained from self-reported participant vaping log during the ad libitum sessions and measured as seconds/minutes between puffs.
|
Days 1-3 of each Arm
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Neal Benowitz, MD, University of California, San Francisco
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Chemically-Induced Disorders
- Substance-Related Disorders
- Tobacco Use Disorder
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Cholinergic Agents
- Ganglionic Stimulants
- Nicotinic Agonists
- Cholinergic Agonists
- Nicotine
Other Study ID Numbers
- 19-27571
- 5R01DA031193 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiovascular Risk Factor
-
University of Southern DenmarkRegion of Southern Denmark; Odense Patient Data Explorative Network; ENIGMA Solutions... and other collaboratorsActive, not recruitingCardiovascular Risk Factor | Risk CommunicationDenmark
-
University of Split, School of MedicineCompletedCardiovascular Risk Factor | Lifestyle Risk ReductionCroatia
-
University of DelawareRecruiting
-
University Health Network, TorontoSunnybrook Health Sciences Centre; MOUNT SINAI HOSPITALRecruitingCardiovascular Risk FactorCanada
-
University of DelawareRecruitingCardiovascular Risk FactorUnited States
-
The Cleveland ClinicActive, not recruitingCardiovascular Risk FactorUnited States
-
University of NebraskaCompletedCardiovascular Risk FactorUnited States
-
Oregon Health and Science UniversityCompleted
-
Dawn BrewerNational Institute of Environmental Health Sciences (NIEHS)Completed
-
Penn State UniversityActive, not recruitingCardiovascular Risk FactorUnited States
Clinical Trials on Low Nicotine E-Liquid
-
Cedars-Sinai Medical CenterTerminatedCoronary Artery Disease | Myocardial PerfusionUnited States
-
Yale UniversityNational Institute on Drug Abuse (NIDA)Not yet recruitingNicotine Use Disorder
-
Virginia Polytechnic Institute and State UniversityCompletedTobacco UseUnited States
-
Yale UniversityNational Institute on Drug Abuse (NIDA)WithdrawnElectronic Cigarette UseUnited States
-
Wake Forest University Health SciencesNational Institute on Drug Abuse (NIDA); University of PennsylvaniaCompleted
-
American University of Beirut Medical CenterNational Institute on Drug Abuse (NIDA); National Institutes of Health (NIH)RecruitingNicotine Dependence | Nicotine Vaping | Nicotine AddictionLebanon
-
Yale UniversityNational Institute on Drug Abuse (NIDA)Not yet recruiting
-
Yale UniversityNational Institute on Drug Abuse (NIDA)RecruitingCigarette Smoking | Sex Differences | Nicotine Addiction | E-Cig UseUnited States
-
University of Southern CaliforniaCompletedElectronic Cigarette Use | Cigarette Smoking | Cigarette Use, Electronic | VapingUnited States
-
Wake Forest University Health SciencesNational Institute on Drug Abuse (NIDA); National Institutes of Health (NIH)CompletedTobacco UseUnited States